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Could you begin by introducing the function 
of primary cilia within the body? 
SMN: The ability of primary cilia to sense fluid 
flow is probably their best studied function. 
This enables ciliated cells to sense urine flow 
in the kidney, blood flow in the vasculature, 
hepatic bile in the liver, digestive fluid in the 
pancreas, lacunocanalicular fluid in bone or 
cartilage, and more. 
Collaborating with Dr Wissam AbouAlaiwi at 
the University of Toledo, USA, we found that 
primary cilia can regulate cell division and 
DNA content, and help the cell to locate itself 
within the microenvironment – a process also 
known as planar cell polarity. Most recently, 
our laboratory has also found a chemical-
specific sensory function of primary cilia in 
both vascular endothelia and renal epithelia.
Aside from the 
mechanosensory, 
chemosensory 
and regulatory cell 
division functions of 
primary cilia, other 
laboratories have also 
discovered the roles 
of primary cilia in 
gravitational sensing, 
regulating cell 
volume, identifying left-right body formation 
during embryogenesis, directing cell migration, 
and many others.
Why is it important to gain a solid 
understanding of the molecular and 
biophysical properties of mechanosensory 
and chemosensory primary cilia?
KFA: The importance of primary cilia has only 
just begun to be understood. When a cell loses 
sensory input from its antenna-like cilium, it 
cannot respond to environmental cues and 
changes. The mechanosensation of primary 
cilia occurs principally in response to fluid shear 
stress, while chemosensation refers to the cell’s 
ability to sense chemical cues such as ligands in 
the blood or neurotransmitters in the synapse. 
Dysfunctional cilia are known to be the cause of 
a group of diseases termed ciliopathies, which 
include polycystic kidney disease (PKD), Bardet-
Biedl syndrome, and primary ciliary dyskinaesia. 
These diseases are caused by mutated proteins 
in the primary cilium or centrosome. The 
association between cilia and centrioles has 
opened the possibility for cilia having a role in 
cell division and potentially being a good target 
in cancer therapy.
Can you describe the translational work you 
are undertaking? How are you developing 
ciliotherapies to help patients?
SHK: Our research focused on primary cilia 
has two goals. The first is to explore the 
molecular components of cilia-regulated 
signalling pathways. Understanding these would 
allow scientists to intervene in the molecular 
mechanisms in the hope of correcting abnormal 
molecular pathways of the cell. The second goal 
is to utilise the knowledge gained to directly 
target primary cilia. We achieve this by screening 
thousands of small molecules and asking if any 
of these compounds would affect primary cilia 
function or structure. Then, we examine whether 
and how any alteration would affect cilia-
regulated signalling pathways in disease.
How did you come to work in this field? To 
what extent has collaboration shaped the 
research you have conducted?
Drs Surya M Nauli, Kimberly F Atkinson and Sarmed H Kathem describe their innovative research 
in primary cilia and the many international collaborations that have enabled their success
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SMN: We came to learn about the primary 
cilia while completing our National Institutes 
of Health (NIH) fellowships with Dr Jing 
Zhou at Harvard Medical School in the US, 
working on an exciting project related to 
PKD. Dr Zhou then introduced me to Dr Ken 
Spring, who was an outstanding scientist 
from NIH. He was the fi rst to directly 
activate mechanical function of cilia using a 
micropipette. Dr Spring visited Boston many 
times to instruct me in using microscopy to 
study this mechanosensory function further. 
We were also lucky enough to be guided by 
Drs Don Ingber and Joe Bonventre, experts 
in cell mechanics and renal physiology. Our 
laboratory is currently working on the roles 
of primary cilia in the cardiovascular system. 
We have thus collaborated with our mentor 
and colleague, Dr William Pearce, who is a 
renowned cardiovascular physiologist. Having 
such wonderful mentors provided us with 
excellent experiences and enabled us to attain 
a successful research career in cilia biology. 
Have any results surprised you thus far? 
S MN: Our group has provided a potential new 
cellular mechanism for fenoldopam. It was 
previously known that fenoldopam-induced 
hypotension was achieved by increasing kidney 
fi ltration, but the mechanism by which this 
occurred was not understood. Our surprising 
data show that the fenoldopam receptor is 
exclusively located in the cilia. Activating this 
receptor increases cilia length, improving their 
function, which in turn induces vasodilation and 
increases the kidney (glomerular) fi ltration rate.
POLYCYSTIC KIDNEY DISEASE (PKD) is the 
most common life-threatening genetic disease 
worldwide – affecting about 12.5 million people. 
Patients with the condition have multiple fl uid-
fi lled cysts in their kidneys that lead to a massive 
enlargement of the organ and gradual worsening 
of its function, as well as complete failure in many 
cases. The lack of available treatment means 
patients may eventually require regular dialysis or 
a kidney transplant. 
Known as a ciliopathy, PKD is caused by 
dysfunction of the primary cilia on the renal 
epithelial cells lining the ducts within the kidney. 
Primary cilia are microscopic hair-like structures 
found on the surface of most mammalian 
cells; however, until the 1990s they were not 
considered important for cell function. Unlike 
the motile cilia that cover certain types of cell 
and move in a coordinated manner, only one 
non-motile primary cilium is present on each 
cell, increasing its surface area for important 
roles in sensing a variety of chemical and 
mechanical signals. 
Primary cilia are mechanosensitive; they 
bend in response to fl uid-shear stress and 
provide information about the external fl uid 
environment to the cell. Dr Surya M Nauli from 
Chapman University, USA, has spent many 
years investigating the roles of primary cilia 
in PKD and other diseases. In collaboration 
with his colleagues, Drs Sarmed H Kathem 
and Kimberly F Atkinson, his team is focusing 
on how interrupting a cell’s ability to detect 
fl uid fl ow leads to disease. “Fluid fl ow-induced 
intracellular signalling regulates various cellular 
functions like planar cell polarity, cell division 
and differentiation,” Kathem elucidates. “As 
PKD patients have dysfunctional fl uid fl ow 
mechanosensation, this signalling is also 
impaired and, consequently, disorientated renal 
cell divisions lead to the formation of cysts – the 
prominent feature of PKD.” It is therefore vital 
to obtain a better understanding of primary 
cilial function in the body, with the ultimate aim 
of developing new ways of treating ciliopathies.
CILIAL FUNCTION
PKD is typically caused by a mutation in one of two 
genes, PKD1 or PKD2, which encode polycystin 1 
(PC1) and PC2 respectively. Both of these proteins 
are found on the surface of the cell, localised on 
the primary cilium. PC1 has a long structure that 
reaches out into the cell’s environment, while PC2 
is a calcium-permeable cation channel. The two 
form a polycystin complex on the surface of the 
primary cilium, which, when activated, can signal 
inside the cell. 
The team was able to uncover the link between 
these proteins and PKD. “Among other ciliary 
proteins, Nauli’s research showed that PC1 and 
PC2 function as mechanosensory proteins,” 
Kathem reveals. “Owing to the unique ciliary 
localisation of these proteins, when primary cilia 
are bent by the fl uid fl ow, these ciliary proteins 
undergo a structural conformation change and 
evoke intracellular signals that regulate many 
cellular functions.” Nauli’s early work showed 
that blocking the function of either PC1 or PC2 
was enough to stop kidney epithelial cells from 
perceiving the mechanical cues of fl uid fl ow, which 
could lead to the regulation of tissue growth and 
result in the development of cysts. 
Nauli and his colleagues succeeded in defi ning 
the roles that PC1 and PC2 play in primary 
cilia mechanosensation. The long extracellular 
domain of PC1 extends out into the cell’s 
microenvironment and acts as a lever to amplify 
stresses at the cell surface, transmitting the 
signal to its tightly-associated PC2 channel. 
The channel then opens to allow calcium ions 
to enter the cell in a fl ow-induced manner, 
enabling the cell to understand the fl uid 
dynamics of its external environment and 
inducing gene expression to regulate growth. 
This knowledge was very important for 
deepening the researchers’ understanding of 
PKD and providing potential targets for future 
therapeutic development. “The search for 
therapy to treat cilia-associated diseases is, no 
doubt, a very complex process,” Nauli explains. 
“It will take years or even decades to accomplish 
and validate its safety and effectiveness toward 
our patients, but we think that we are on the 
right path to tackle the challenges.” 
PKD, HYPERTENSION AND ANEURYSM
In addition to cyst formation in their kidneys, 
patients with PKD often develop high blood 
pressure, which manifests around a decade 
earlier than in non-PKD patients, as well as other 
cardiovascular conditions such as aneurysm. 
Interestingly, this is unlikely to be due to the 
failing kidney. “PKD patients have hypertension 
that emerges early in life, even before renal 
function deterioration, which supports the 
hypothesis that hypertension in PKD is not 
solely the result of a cystic kidney, but rather 
stems from inherited endothelial dysfunction,” 
Kathem explains. The endothelial cells lining 
the blood vessels are known to be able to sense 
fl uid shear stress. The mechanostimulation of the 
cells causes an infl ux of calcium to initiate the 
biosynthesis and release of nitric oxide, which 
controls vascular contraction and therefore 
regulates blood pressure. The same infl ux of 
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calcium also initiates a complex signalling 
cascade to regulate survivin expression and 
aneurysm formation.
Nauli and his colleagues used mice lacking PC1, 
PC2 or primary cilia to show that primary cilia 
are responsible for the initial mechanosensation 
of the endothelial cells, using the same PC1-PC2 
signalling complex seen in the kidney epithelial 
cells. Cells from PKD patients confi rmed that 
this protein is missing from cilia in their vascular 
endothelium – which are therefore unable to 
transmit information about increased blood fl ow – 
do not release nitric oxide to stimulate vasodilation 
and do not properly maintain blood vessel 
architecture. This important discovery explains the 
hypertension and aneurysm of PKD patients, and 
provides further evidence to show that primary 
cilia are mechanosensory microcompartments 
important for a range of biological activities. “The 
different cell types in the kidney and vasculature 
perform different functions, and having abnormal 
cilia will have different physiological effects,” 
points out Atkinson. “The underlying problem is 
the inability of these cells to respond to mechanical 
stimulation of fl uid fl ow, thereby affecting renal 
morphology, vascular architecture, vascular tone 
and blood pressure.”  
CHEMOSENSATORY TREATMENT
The length of primary cilia is very important for 
their ability to function, which is why they are 
highly regulated. In the kidneys, cilia are longer 
in wider tubules than in narrower ones. Nauli 
discovered the molecular interactions that 
regulate ciliary length by rearranging the cell’s 
structural elements. He and Kathem began to 
screen a range of compounds that might alter 
cilial length in order to improve their function. 
One promising candidate was fenoldopam, a 
drug currently used to treat hypertension, which 
stimulated the ciliary chemosensory pathway. 
When Nauli and his team tested the drug on a 
PKD mouse model, both the length of cilia in 
the vascular endothelium and the level of nitric 
oxide in the blood increased. Clinical trials in 
PKD patients showed that dopamine agonist 
treatment led to a reduction in blood pressure, 
a groundbreaking result that provided the fi rst 
example of a ciliotherapy capable of restoring 
primary cilia function in ciliopathic patients. 
“Our studies further show that ciliotherapy is a 
promising way to treat cilia-associated diseases, 
and we are still working on a more effi cient agent 
that could restore cilia function and thus relieve 
hypertension,” Kathem elaborates. 
The group’s research has highlighted the 
importance of primary cilial function by providing 
a deeper understanding of the ciliopathies that 
can lead to disease. Nauli and his team are working 
on the basic biology of these structures and the 
translation of this knowledge into therapeutics 
for the future. “Understanding the molecular and 
biophysical basis of cilia function is key to the 
development of drugs that target the primary cilia 
to treat disease,” Atkinson concludes. 
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SURYA M NAULI received his PhD in 
Pharmacology from Loma Linda Medical 
School, USA. Specifi c areas currently under 
investigation in his laboratory include 
molecular, cellular and biophysical studies 
of primary cilia; chemical screening for 
pharmacological candidates in vitro; and 
development of a more effi cient in vivo system 
to further characterise the cilia-targeting 
therapy in vascular and kidney diseases. Surya’s 
research and clinical teams are currently 
completing a clinical study strategised for a 
targeted therapy in hypertensive patients.
KIMBERLY F ATKINSON earned her PhD in 
Molecular  Medicine  and  Translational  Science 
from  Wake  Forest  School  of Medicine, 
USA.  She is currently working on the role 
of primary cilia in human disease. Potential 
avenues of research include the involvement 
of primary cilia in ciliopathies such as PKD and 
targeting the centrosome and primary cilia in 
cancer therapy. 
SARMED H KATHEM completed his PhD in 
Pharmacology in 2012 with a thesis focusing on 
the roles of primary cilia. He was immediately 
appointed as a tenured faculty member in the 
College of Pharmacy, University of Baghdad, 
Iraq. Kathem’s research includes in vitro 
and in vivo models and clinical studies. His 
clinical expertise includes PKD, hypertension 
and ciliotherapy. 
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